Search Results for: HRAS

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
ARHGAP29 Rho GTPase activating protein 29
  • Rho GTPase cycle
ARHGEF1 Rho guanine nucleotide exchange factor 1
  • NRAGE signals death through JNK
  • Rho GTPase cycle
  • G alpha (12/13) signalling events
ARHGEF18 Rho/Rac guanine nucleotide exchange factor 18
  • NRAGE signals death through JNK
  • Rho GTPase cycle
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • G alpha (12/13) signalling events
BCL2 BCL2 apoptosis regulator
  • Activation of BAD and translocation to mitochondria
  • BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members
  • Interleukin-4 and Interleukin-13 signaling
  • The NLRP1 inflammasome
  • Estrogen-dependent gene expression
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • Ibuprofen
  • Paclitaxel
  • Docetaxel
  • Rasagiline
  • Paclitaxel docosahexaenoic acid
  • Apoptone
  • Glycine betaine
  • Eribulin
  • Dexibuprofen
  • Isosorbide
  • Venetoclax
  • Obatoclax
  • Navitoclax
  • Choriocarcinoma
  • Gastric cancer
  • Chronic lymphocytic leukemia (CLL)
  • Small cell lung cancer
  • Kaposi's sarcoma
  • Nasopharyngeal cancer
  • Cervical cancer
BLID BH3-like motif containing, cell death inducer
BMPR1A bone morphogenetic protein receptor type 1A
  • Signaling by BMP
  • Dibotermin alfa
  • Hereditary mixed polyposis syndrome
  • Juvenile polyposis syndrome
BRAF B-Raf proto-oncogene, serine/threonine kinase
  • Spry regulation of FGF signaling
  • Frs2-mediated activation
  • Frs2-mediated activation
  • ARMS-mediated activation
  • Signalling to p38 via RIT and RIN
  • RAF activation
  • MAP2K and MAPK activation
  • Negative feedback regulation of MAPK pathway
  • Negative regulation of MAPK pathway
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Signaling by MRAS-complex mutants
  • Sorafenib
  • XL281
  • RAF-265
  • PLX-4720
  • N-{2,4-difluoro-3-[(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]phenyl}ethanesulfonamide
  • (1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime
  • Vemurafenib
  • Regorafenib
  • Dabrafenib
  • Encorafenib
  • Fostamatinib
  • Ripretinib
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
  • Thyroid cancer
  • Malignant melanoma
BRAP BRCA1 associated protein
  • RAF activation
  • Negative regulation of MAPK pathway
  • Signaling by moderate kinase activity BRAF mutants
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Signaling downstream of RAS mutants
BUB1 BUB1 mitotic checkpoint serine/threonine kinase
  • Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal
  • Separation of Sister Chromatids
  • Resolution of Sister Chromatid Cohesion
  • RHO GTPases Activate Formins
  • Mitotic Prometaphase
  • EML4 and NUDC in mitotic spindle formation
CAV1 caveolin 1
  • Triglyceride catabolism
  • eNOS activation
  • NOSTRIN mediated eNOS trafficking
  • Basigin interactions
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • VEGFR2 mediated vascular permeability
  • Extra-nuclear estrogen signaling
  • FOXO-mediated transcription of cell cycle genes
  • Congenital generalized lipodystrophy (CGL)
CDC123 cell division cycle 123
CDC25A cell division cycle 25A
  • Transcription of E2F targets under negative control by DREAM complex
  • Polo-like kinase mediated events
  • Activation of ATR in response to replication stress
  • Ub-specific processing proteases
  • Cyclin E associated events during G1/S transition
  • Cyclin A/B1/B2 associated events during G2/M transition
  • Ubiquitin Mediated Degradation of Phosphorylated Cdc25A
  • Cyclin A:Cdk2-associated events at S phase entry
  • Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
CDC25C cell division cycle 25C
  • Polo-like kinase mediated events
  • Activation of ATR in response to replication stress
  • RHO GTPases activate PKNs
  • TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
  • TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain
  • Cyclin A/B1/B2 associated events during G2/M transition
  • Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
  • Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
CDH1 cadherin 1
  • Degradation of the extracellular matrix
  • Degradation of the extracellular matrix
  • Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
  • Integrin cell surface interactions
  • Apoptotic cleavage of cell adhesion proteins
  • Adherens junctions interactions
  • RHO GTPases activate IQGAPs
  • InlA-mediated entry of Listeria monocytogenes into host cells
  • Gastric cancer
  • Penile cancer
  • Nasopharyngeal cancer
  • Breast cancer
  • Hepatocellular carcinoma
  • Thyroid cancer
CDKN2A cyclin dependent kinase inhibitor 2A
  • Oxidative Stress Induced Senescence
  • Senescence-Associated Secretory Phenotype (SASP)
  • Oncogene Induced Senescence
  • Cyclin D associated events in G1
  • Transcriptional Regulation by VENTX
  • Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4
  • Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
  • Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4
  • Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
  • Apoptotic factor-mediated response
  • Oxidative Stress Induced Senescence
  • Oncogene Induced Senescence
  • SUMOylation of DNA damage response and repair proteins
  • SUMOylation of transcription factors
  • Regulation of TP53 Degradation
  • Stabilization of p53
  • Regulation of RUNX3 expression and activity
  • Defective Intrinsic Pathway for Apoptosis Due to p14ARF Loss of Function
  • Evasion of Oncogene Induced Senescence Due to p14ARF Defects
  • Evasion of Oxidative Stress Induced Senescence Due to p14ARF Defects
  • Bladder cancer
  • Type II diabetes mellitus
  • Pancreatic cancer
  • Burkitt lymphoma
  • Adult T-cell leukemia
  • Malignant pleural mesothelioma
  • Non-small cell lung cancer
  • Chronic myeloid leukemia (CML)
  • Oral cancer
  • Penile cancer
  • Nasopharyngeal cancer
  • Glioma
  • Osteosarcoma
  • Squamous cell carcinoma
  • Cholangiocarcinoma
  • Gallbladder cancer
  • Malignant islet cell carcinoma
  • Laryngeal cancer
  • Hepatocellular carcinoma
  • Esophageal cancer
  • Malignant melanoma
CTNNA1 catenin alpha 1
  • Adherens junctions interactions
  • VEGFR2 mediated vascular permeability
  • Myogenesis
  • Myogenesis
  • RHO GTPases activate IQGAPs
CXCL1 C-X-C motif chemokine ligand 1
  • Chemokine receptors bind chemokines
  • G alpha (i) signalling events
  • Interleukin-10 signaling
  • Neutrophil degranulation
DEAF1 DEAF1 transcription factor
DGKE diacylglycerol kinase epsilon
  • Effects of PIP2 hydrolysis
  • alpha-Tocopherol succinate
DGKZ diacylglycerol kinase zeta
  • Effects of PIP2 hydrolysis
  • alpha-Tocopherol succinate

Page 2 out of 8 pages